Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alaproclate
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alaproclate is a small molecule antidepressant that was developed in the 1970s by Astra AB (now AstraZeneca) as one of the first selective serotonin reuptake inhibitors (SSRIs). It acts primarily by inhibiting neuronal serotonin reuptake, thereby increasing serotonin levels in the synaptic cleft. In addition to its SSRI activity, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, though it does not exhibit discriminative stimulus properties similar to phencyclidine. The drug was investigated for use in depression and dementia but development was discontinued due to concerns over hepatotoxicity observed in animal studies[1][3][6][7].
- Other names
- alaproclate hydrochloride
02
Targets
SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on alaproclate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alaproclate.